A conditional replication-competent adenoviral vector, AD-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis

S. Matsubara, Y. Wada, T. A. Gardner, M. Egawa, M. S. Par, C. L. Hsieh, H. E. Zhau, C. Kao, S. Kamidono, J. Y. Gillenwater, L. W K Chung

Research output: Contribution to journalArticle

133 Citations (Scopus)

Abstract

Prostate cancer has a high propensity to metastasize to bone, which often resists hormone, radiation, and chemotherapies. Because of the reciprocal nature of the prostate cancer and bone stroma interaction, we designed a cotargeting strategy using a conditional replication-competent adenovirus to target the growth of tumor cells and their associated osteoblasts. The recombinant Ad-OC-E1a was constructed using a noncollagenous bone matrix protein osteocalcin (OC) promoter to drive the viral early E1a gene with restricted replication in cells that express OC transcriptional activity. Unlike Ad-PSE-E1a, Ad-OC-E1a was highly efficient in inhibiting the growth of PSA-producing (LNCaP, C4-2, and ARCaP) and nonproducing (PC-3 and DU145) human prostate cancer cell lines. This virus was also found to effectively inhibit the growth of human osteoblasts and human prostate stromal cells in vitro. Athymic mice bearing s.c. androgen receptor-negative and PSA-negative PC-3 xenografts responded to a single intratumoral administration of 2 ×109 plaque-forming unit(s) of Ad-OC-E1a. In SCID/bg mice, intraosseous growth of androgen receptor-positive and PSA-producing C4-2 xenografts responded markedly to i.v. administrations of a single dose of Ad-OC-E1a. One hundred percent of the treated mice responded to this systemic Ad-OC-E1a therapy with a decline of serum PSA to an undetectable level, and 80% of the mice with PSA rebound responded to the second dose of systemic Ad-OC-E1a. Forty percent of the mice were found to be cured by systemic Ad-OC-E1a without subsequent PSA rebound or tumor cells found in the skeleton. This cotargeting strategy shows a broader spectrum and appears to be more effective than systemic Ad-PSE-E1a in preclinical models of human prostate cancer skeletal metastasis.

Original languageEnglish
Pages (from-to)6012-6019
Number of pages8
JournalCancer Research
Volume61
Issue number16
Publication statusPublished - Aug 15 2001
Externally publishedYes

Fingerprint

Bone Neoplasms
Osteocalcin
Androgens
Prostatic Neoplasms
Theoretical Models
Neoplasm Metastasis
Androgen Receptors
Growth
Osteoblasts
Heterografts
Bone Matrix
SCID Mice
Stromal Cells
Adenoviridae
Nude Mice
Skeleton
Prostate
Neoplasms
Hormones
Radiation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A conditional replication-competent adenoviral vector, AD-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. / Matsubara, S.; Wada, Y.; Gardner, T. A.; Egawa, M.; Par, M. S.; Hsieh, C. L.; Zhau, H. E.; Kao, C.; Kamidono, S.; Gillenwater, J. Y.; Chung, L. W K.

In: Cancer Research, Vol. 61, No. 16, 15.08.2001, p. 6012-6019.

Research output: Contribution to journalArticle

Matsubara, S, Wada, Y, Gardner, TA, Egawa, M, Par, MS, Hsieh, CL, Zhau, HE, Kao, C, Kamidono, S, Gillenwater, JY & Chung, LWK 2001, 'A conditional replication-competent adenoviral vector, AD-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis', Cancer Research, vol. 61, no. 16, pp. 6012-6019.
Matsubara, S. ; Wada, Y. ; Gardner, T. A. ; Egawa, M. ; Par, M. S. ; Hsieh, C. L. ; Zhau, H. E. ; Kao, C. ; Kamidono, S. ; Gillenwater, J. Y. ; Chung, L. W K. / A conditional replication-competent adenoviral vector, AD-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. In: Cancer Research. 2001 ; Vol. 61, No. 16. pp. 6012-6019.
@article{f435b5498f184b2eb576b05fc5793063,
title = "A conditional replication-competent adenoviral vector, AD-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis",
abstract = "Prostate cancer has a high propensity to metastasize to bone, which often resists hormone, radiation, and chemotherapies. Because of the reciprocal nature of the prostate cancer and bone stroma interaction, we designed a cotargeting strategy using a conditional replication-competent adenovirus to target the growth of tumor cells and their associated osteoblasts. The recombinant Ad-OC-E1a was constructed using a noncollagenous bone matrix protein osteocalcin (OC) promoter to drive the viral early E1a gene with restricted replication in cells that express OC transcriptional activity. Unlike Ad-PSE-E1a, Ad-OC-E1a was highly efficient in inhibiting the growth of PSA-producing (LNCaP, C4-2, and ARCaP) and nonproducing (PC-3 and DU145) human prostate cancer cell lines. This virus was also found to effectively inhibit the growth of human osteoblasts and human prostate stromal cells in vitro. Athymic mice bearing s.c. androgen receptor-negative and PSA-negative PC-3 xenografts responded to a single intratumoral administration of 2 ×109 plaque-forming unit(s) of Ad-OC-E1a. In SCID/bg mice, intraosseous growth of androgen receptor-positive and PSA-producing C4-2 xenografts responded markedly to i.v. administrations of a single dose of Ad-OC-E1a. One hundred percent of the treated mice responded to this systemic Ad-OC-E1a therapy with a decline of serum PSA to an undetectable level, and 80{\%} of the mice with PSA rebound responded to the second dose of systemic Ad-OC-E1a. Forty percent of the mice were found to be cured by systemic Ad-OC-E1a without subsequent PSA rebound or tumor cells found in the skeleton. This cotargeting strategy shows a broader spectrum and appears to be more effective than systemic Ad-PSE-E1a in preclinical models of human prostate cancer skeletal metastasis.",
author = "S. Matsubara and Y. Wada and Gardner, {T. A.} and M. Egawa and Par, {M. S.} and Hsieh, {C. L.} and Zhau, {H. E.} and C. Kao and S. Kamidono and Gillenwater, {J. Y.} and Chung, {L. W K}",
year = "2001",
month = "8",
day = "15",
language = "English",
volume = "61",
pages = "6012--6019",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "16",

}

TY - JOUR

T1 - A conditional replication-competent adenoviral vector, AD-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis

AU - Matsubara, S.

AU - Wada, Y.

AU - Gardner, T. A.

AU - Egawa, M.

AU - Par, M. S.

AU - Hsieh, C. L.

AU - Zhau, H. E.

AU - Kao, C.

AU - Kamidono, S.

AU - Gillenwater, J. Y.

AU - Chung, L. W K

PY - 2001/8/15

Y1 - 2001/8/15

N2 - Prostate cancer has a high propensity to metastasize to bone, which often resists hormone, radiation, and chemotherapies. Because of the reciprocal nature of the prostate cancer and bone stroma interaction, we designed a cotargeting strategy using a conditional replication-competent adenovirus to target the growth of tumor cells and their associated osteoblasts. The recombinant Ad-OC-E1a was constructed using a noncollagenous bone matrix protein osteocalcin (OC) promoter to drive the viral early E1a gene with restricted replication in cells that express OC transcriptional activity. Unlike Ad-PSE-E1a, Ad-OC-E1a was highly efficient in inhibiting the growth of PSA-producing (LNCaP, C4-2, and ARCaP) and nonproducing (PC-3 and DU145) human prostate cancer cell lines. This virus was also found to effectively inhibit the growth of human osteoblasts and human prostate stromal cells in vitro. Athymic mice bearing s.c. androgen receptor-negative and PSA-negative PC-3 xenografts responded to a single intratumoral administration of 2 ×109 plaque-forming unit(s) of Ad-OC-E1a. In SCID/bg mice, intraosseous growth of androgen receptor-positive and PSA-producing C4-2 xenografts responded markedly to i.v. administrations of a single dose of Ad-OC-E1a. One hundred percent of the treated mice responded to this systemic Ad-OC-E1a therapy with a decline of serum PSA to an undetectable level, and 80% of the mice with PSA rebound responded to the second dose of systemic Ad-OC-E1a. Forty percent of the mice were found to be cured by systemic Ad-OC-E1a without subsequent PSA rebound or tumor cells found in the skeleton. This cotargeting strategy shows a broader spectrum and appears to be more effective than systemic Ad-PSE-E1a in preclinical models of human prostate cancer skeletal metastasis.

AB - Prostate cancer has a high propensity to metastasize to bone, which often resists hormone, radiation, and chemotherapies. Because of the reciprocal nature of the prostate cancer and bone stroma interaction, we designed a cotargeting strategy using a conditional replication-competent adenovirus to target the growth of tumor cells and their associated osteoblasts. The recombinant Ad-OC-E1a was constructed using a noncollagenous bone matrix protein osteocalcin (OC) promoter to drive the viral early E1a gene with restricted replication in cells that express OC transcriptional activity. Unlike Ad-PSE-E1a, Ad-OC-E1a was highly efficient in inhibiting the growth of PSA-producing (LNCaP, C4-2, and ARCaP) and nonproducing (PC-3 and DU145) human prostate cancer cell lines. This virus was also found to effectively inhibit the growth of human osteoblasts and human prostate stromal cells in vitro. Athymic mice bearing s.c. androgen receptor-negative and PSA-negative PC-3 xenografts responded to a single intratumoral administration of 2 ×109 plaque-forming unit(s) of Ad-OC-E1a. In SCID/bg mice, intraosseous growth of androgen receptor-positive and PSA-producing C4-2 xenografts responded markedly to i.v. administrations of a single dose of Ad-OC-E1a. One hundred percent of the treated mice responded to this systemic Ad-OC-E1a therapy with a decline of serum PSA to an undetectable level, and 80% of the mice with PSA rebound responded to the second dose of systemic Ad-OC-E1a. Forty percent of the mice were found to be cured by systemic Ad-OC-E1a without subsequent PSA rebound or tumor cells found in the skeleton. This cotargeting strategy shows a broader spectrum and appears to be more effective than systemic Ad-PSE-E1a in preclinical models of human prostate cancer skeletal metastasis.

UR - http://www.scopus.com/inward/record.url?scp=0035881263&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035881263&partnerID=8YFLogxK

M3 - Article

C2 - 11507044

AN - SCOPUS:0035881263

VL - 61

SP - 6012

EP - 6019

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 16

ER -